Supervised dosing with a long‐acting medication vs unsupervised consumption
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
- Supervised dosing with a long‐acting opioid medication in the management of opioid dependence 2017 · Cochrane Headline outcomes onlyRR 0.63 [0.1, 3.86]2 studies · 363 participantsVery low